AI-Native Scoping Reviews & Evidence Mapping

Deep vein thrombosis is not one disease trigger, but a convergence of risk: genes, cancer, surgery, catheters, hormones, infection, inflammation, and immobility can all push the body toward clot formation. This review maps where the strongest danger signals appear — from COVID-19 and oral contraceptives to cancer care and inherited thrombophilia — and shows why modern DVT prevention must be personalized rather than one-size-fits-all.

This review shows that DVT is not just a problem of stasis — it is a biologically active inflammatory process driven by endothelial injury, platelet–leukocyte crosstalk, and NET-mediated immunothrombosis. Read the full paper to see which mechanisms are strongest, which patient phenotypes carry the clearest signals, and which emerging biomarkers and targets could reshape risk stratification and therapy.

This paper shows that DCB is not just a technical upgrade over POBA, but a consistently stronger strategy for restenosis-prone vascular disease, with better patency and fewer repeat interventions across coronary ISR, femoropopliteal lesions, BTK disease, and dialysis access. The full paper is worth reading because it reveals where that advantage is most convincing, where technique and vessel preparation change the outcome, and how much of DCB’s real-world value lies in selecting the right lesion, not just the device.

The paper tackles one of endovascular medicine’s most controversial questions: whether DCBs truly carry a late mortality risk. Mapping 170 original studies, it shows why the feared signal largely fades in broader evidence, where comorbidity and indication matter more than the device itself — and reveals the few settings where uncertainty still remains.

CLTI/CLI is not always the end of the road: this review maps the emerging alternatives that may help selected “no-option” patients avoid or delay amputation, from cell and gene therapy to venous arterialization, retrograde access, and adjunctive pharmacology. The full paper shows where the evidence is clinically promising, where it remains experimental, and which strategies may realistically enter limb-salvage practice next.

This review maps 260 original studies and 80,624 participants into a practical evidence layer on where coil embolization helps in aortic aneurysm repair — especially type II endoleak prevention, sac behavior, and staged spinal-cord-protection strategies. It also shows the trade-offs that matter clinically: recurrent endoleaks, buttock claudication, radiation exposure, infection risk, coil migration, and when coils, plugs, Onyx, NBCA, or anatomy-driven alternatives may be preferable.

CLTI prognosis is not decided by the artery alone: this evidence map shows that wound severity, nutrition, frailty, heart failure, dialysis, mobility loss, and biomarkers together define who survives, heals, or loses a limb. The full review explains which clinical scores and warning signals may help identify high-risk patients before revascularization decisions are made.

This paper shows that vascular calcification in CKD is not a passive byproduct of renal failure, but an active, biologically driven process fueled by phosphate burden, uremic toxins, inflammation, and VSMC transdifferentiation. The full paper is worth reading because it maps where the strongest mechanistic and clinical signals converge across 1,230 original studies, and highlights which biomarkers and interventions may actually become actionable in routine CKD care.

This paper shows that the choice between carotid endarterectomy and carotid stenting is not just a technical preference, but a clinically meaningful trade-off between stroke risk, myocardial infarction risk, and long-term durability. Read the full paper to see which patients truly benefit from CEA as the default option, where CAS still has a justified role, and how 670 original studies map the evidence behind that decision.

PSV is not just a number for grading carotid stenosis—it can signal restenosis risk, hemodynamic compromise, plaque instability, and response to revascularization, but only when interpreted in the right anatomical and technical context. Read the full paper to see where PSV truly adds clinical value, where it can mislead, and how the evidence supports smarter carotid ultrasound decision-making.

This paper shows that carotid stenosis is not a rare incidental finding but a patterned disease concentrated in stroke, TIA, and clearly defined high-risk groups—while broad screening in low-yield populations adds little. It is worth reading because it maps where carotid imaging truly matters and why future risk assessment may need to move beyond percent narrowing toward plaque vulnerability.

Carotid stenosis outcomes are not determined by narrowing alone: this review shows how symptom status, procedure choice, restenosis, and plaque vulnerability markers can decisively shift stroke risk and long-term prognosis. Read the full paper to see which patients appear to benefit from intervention, where CEA and CAS truly diverge, and why modern risk stratification may need to move beyond luminal stenosis.